New South Capital Management Inc. Sells 20,663 Shares of Hologic, Inc. (NASDAQ:HOLX)

New South Capital Management Inc. trimmed its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 11.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 164,625 shares of the medical equipment provider's stock after selling 20,663 shares during the quarter. New South Capital Management Inc. owned approximately 0.07% of Hologic worth $10,169,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC raised its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares during the period. Smithfield Trust Co raised its stake in shares of Hologic by 160.0% in the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 400 shares during the period. Raiffeisen Bank International AG purchased a new position in shares of Hologic during the 4th quarter valued at $49,000. Finally, West Financial Advisors LLC bought a new position in shares of Hologic during the 1st quarter worth $50,000. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of research reports. Raymond James Financial restated an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a research note on Friday, May 2nd. Wall Street Zen cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Evercore ISI dropped their price objective on Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Finally, Royal Bank Of Canada cut their target price on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Hologic has an average rating of "Hold" and an average price target of $77.42.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus acquired 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director owned 5,445 shares of the company's stock, valued at $300,781.80. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is currently owned by insiders.

Hologic Price Performance

NASDAQ:HOLX traded down $0.57 during mid-day trading on Thursday, reaching $64.74. The stock had a trading volume of 1,233,581 shares, compared to its average volume of 2,373,435. The stock has a market capitalization of $14.43 billion, a P/E ratio of 27.31, a P/E/G ratio of 2.39 and a beta of 0.55. The firm has a 50 day moving average price of $60.58 and a two-hundred day moving average price of $63.81. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period last year, the firm posted $1.03 earnings per share. The business's revenue was down 1.2% compared to the same quarter last year. As a group, analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.